Adverse events
ADVERSE EVENTS, ALLERGIC DERMATITIS
No severe or serious AEs were reported during the trial. Overall, 29/49 (59%) enrolled participants experienced at least one transient mild or moderate AEs.The number of participants experiencing AEs and frequency of AEs increased with number of doses during multiple dose stage. Furthermore, during the randomized-controlled trial stage, possibly or probably related AEs were more frequent in the 3d-300 μg/kg ivermectin group (8/11 [73%]) than in the placebo group (3/11 [27%], All adverse events from study drug administration in the intention-to-treat population (n = 49).AEs are given as preferred term (PT), data are n (%), IVM: ivermectin.Study treatment was discontinued in one participant in the placebo group due to allergic dermatitis. Overall, four participants received early antimalarial treatment before day 7, one on 2d-200 μg ivermectin and three in the placebo group. None of the participants on 3d-300 μg/kg ivermectin met criteria for early antimalarial treatment.